
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc is projected to experience significant revenue growth in its PSMA PET imaging segment, with an estimated high-single-digit market share by the first quarter of 2025, reflecting strong upward momentum from previous periods. The company anticipates a reinvigoration of growth for its Pylarify product line, attributed to a new formulary that increases batch sizes by approximately 50% and extends three years of TPT eligibility, effectively enhancing production capacity and potential revenues. Furthermore, improvements in unit and pricing dynamics are expected to materialize through the second half of 2026, supporting a positive outlook for Lantheus's financial performance.
Bears say
Lantheus Holdings Inc. is facing a negative outlook due to its declining growth trajectory, with its two-year growth profile now falling below that of profitable small to mid-cap (SMID) MedTech peers amid lower Pylarify growth forecasts for 2025-2026. The company's Pylarify revenue of $260 million represents an 8% year-over-year decline, which was approximately $14 million short of consensus estimates, marking a significant miss that raises concerns among investors. Additionally, Lantheus experienced lower-than-expected unit growth, achieving only a 2% year-over-year increase, coupled with a notable 10% price headwind during the quarter, further exacerbating the challenges facing its financial performance.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares